Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Abstract

In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.)

Keywords

RosuvastatinMedicineHazard ratioC-reactive proteinRosuvastatin CalciumInternal medicineMyocardial infarctionConfidence intervalStatinPlaceboUnstable anginaCardiologyEndocrinologyGastroenterologyInflammationPathology

Affiliated Institutions

Related Publications

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Donna K. Arnett , Roger S. Blumenthal , Michelle A. Albert +15 more

1. The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life. 2. A team-based ...

2019 Circulation 4477 citations

Publication Info

Year: 2008
Type: article
Volume: 359
Issue: 21
Pages: 2195-2207
Citations: 6445
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

6445

OpenAlex

Cite This

APA Style

                            
                                
                                    Paul M. Ridker, 
                                
                                    Eleanor Danielson, 
                                
                                    Francisco Antônio Helfenstein Fonseca
                                
                                et al.
                            
                            (2008). 
                            Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. 
                            New England Journal of Medicine
                            , 359
                            (21)
                            , 2195-2207.
                            https://doi.org/10.1056/nejmoa0807646
                        

Identifiers

DOI: 10.1056/nejmoa0807646